English
Home > Products > CAS:797-63-7

China CAS:797-63-7 Manufacturer

We aim to understand high quality disfigurement through the output and supply the most beneficial support to domestic and overseas buyers wholeheartedly for CAS:797-63-7, For additional information and facts, please speak to us as quickly as possible!
CAS:797-63-7, High output volume, top quality, timely delivery and your satisfaction are guaranteed. We welcome all inquiries and comments. If you are interested in any of our items or have an OEM order to fulfill, make sure you feel free to contact us now. Working with us will save you money and time.

Related Products

Hot Products

  • Mifepristone

    Mifepristone

    Mifepristone has specifications of CP and IP. DMF and GMP approved.

    CAS:84371-65-3

  • Estriol

    Estriol

    Estriol has CP, EP, USP specifications. DMF under filing.

    CAS:50-27-1

  • Dienogest

    Dienogest

    Dienogest has EP specifications. DMF approved.

    CAS:65928-58-7

  • 6-chloro-1α-chloromethyl-3,20-dioxo-pregna-4,6-dien-17α-acetoxy

    6-chloro-1α-chloromethyl-3,20-dioxo-pregna-4,6-dien-17α-acetoxy

    6-chloro-1α-chloromethyl-3,20-dioxo-pregna-4,6-dien-17α-acetoxy is the intermediate of Cyproterone acetate.

    CAS:17183-98-1

  • Cyproterone Acetate Tablets

    Cyproterone Acetate Tablets

    Cyproterone Acetate Tablets Specifications：50mg*24
    Indications：Anti-androgen
  • Abiraterone

    Abiraterone

    Abiraterone is a steroidal cytochrome P 450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), It is used in combination with prednisone to treat patients with metastatic castration-resistant prostate cancer (prostate cancer that is resistant to medical or surgical treatments that lower testosterone and has already spread to other parts of the body) and metastatic high-risk castration-sensitive prostate cancer.

    CAS:154229-19-3

  • Related Blog
  • Reviews

  • 2019 CPhI China Exhibition Shanghai

    June 2019
    CPhI is the undisputed leader in the pharmaceutical industry. CPhI China offers a key access point to the second largest pharma market in the world. The exhibition features over 3,000 companies and incorporates various API showcases like bioLIVE, iCSE, NEX and FDF, creating a comprehensive platform that connects the entire pharmaceutical industry chain in the Asian-Pacific region.

  • CPHI China 2025 | Looking forward to meeting you!

    CPHI China will be staged at Shanghai New International Expo Center on June 24-26, 2025 together with ICSE & PMEC China,our booth number is W1G20(b).

  • Join Us at Booth N25 for CPHI Korea 2025 in Seoul

  • What Is Finasteride and How Does It Work for Hair Loss and Prostate Health

    Finasteride is one of the most widely researched and prescribed medications for treating male pattern hair loss and benign prostatic hyperplasia (BPH). By targeting the hormonal pathways responsible for hair follicle miniaturization and prostate enlargement, Finasteride has become a cornerstone pharmaceutical ingredient in dermatology and urology. This in-depth guide explores how Finasteride works, its benefits, dosage, safety profile, side effects, comparisons with alternatives, and why global pharmaceutical manufacturers such as Humanwell play a crucial role in its production and supply.

  • Visit Us at IPhEB Russia 2026 – Booth 104

    We welcome all partners, clients and industry professionals to our Booth 104.

  • Can 4-aza-5α-androstan-1-ene-3-oxo-17β-carboxylic Acid Become the Preferred Intermediate for Modern Pharmaceutical Research

    As pharmaceutical innovation continues to advance, the demand for highly pure steroid intermediates has increased significantly. Among these compounds, 4-aza-5α-androstan-1-ene-3-oxo-17β-carboxylic acid has attracted considerable attention due to its unique molecular structure, stability, and importance in the synthesis of several biologically active steroid derivatives.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept